Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Rhapsido (remibrutinib by Year
Rhapsido (remibrutinib — oral BTK inhibitor for chronic spontaneous urticaria CSU, launch Q4 2025) ($M)
Novartis Rhapsido (remibrutinib: $19M in FY2025.
Latest, FY2025
19
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Novartis Form 6-K (0001114448-26-000007)
Where the FY2025 figure comes from
“|| Rhapsido | 19 | nm | nm”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rhapsido (remibrutinib — oral BTK inhibitor for chronic spontaneous urticaria CSU, launch Q4 2025) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
Cite this data
StockData. (2026). Novartis Rhapsido (remibrutinib ($M), annual FY2025–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-rhapsido
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.